Whitehawk Therapeutics, Inc. — Director's Dealing 2018

Sep 26, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aerpio Pharmaceuticals, Inc. (ARPO)
CIK: 0001422142
Period of Report: 2018-09-24

Reporting Person: Castelein Caley (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-09-24	Common Stock	J	268987	$0.00	Acquired	279907	Direct
2018-09-24	Common Stock	D	1603526	$0.00	Disposed	0	Indirect

Footnotes

F1: These shares were received pursuant to a distribution made by Kearny Venture Associates III, LLC in connection with the entity's liquidation.

F2: Consists of (i) 1,571,475 shares of Common Stock owned directly by Kearny Venture Partners, L.P., or KVP, and (ii) 32,051 shares of Common Stock owned directly by Kearny Venture Partners Entrepreneurs Fund, L.P., or KVPE. The general partner of both KVP and KVPE is Kearny Venture Associates, L.L.C., or KVA. KVA has the sole voting and investment control over the shares owned by KVP and KVPE, and the Managing Members of KVA share in the voting and investment control over such shares controlled by KVA. The Managing Members of KVA are Caley Castelein, Richard Spalding and James Shapiro. None of the Managing Members of KVA has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. These shares were distributed to third parties pursuant to a distribution made by the entities in connection with their liquidation.